

Mintu P Turakhia, Mas

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1449077/publications.pdf>

Version: 2024-02-01

206
papers

18,506
citations

41258

49
h-index

13727

129
g-index

213
all docs

213
docs citations

213
times ranked

24287
citing authors

#	ARTICLE	IF	CITATIONS
1	Evaluation of Quality of Care for US Veterans With Recent-Onset Heart Failure With Reduced Ejection Fraction. <i>JAMA Cardiology</i> , 2022, 7, 130.	3.0	19
2	Achievement and quality measure attainment in patients hospitalized with atrial fibrillation: Results from The Get With The Guidelines “Atrial Fibrillation (GWTC-AFIB) registry. <i>American Heart Journal</i> , 2022, 245, 90-99.	1.2	2
3	The Gig Economy Worker—A New Social Determinant of Health?. <i>JAMA Cardiology</i> , 2022, 7, 125.	3.0	5
4	Is it time for a consumerized or home-based 12-lead electrocardiogram?. <i>Europace</i> , 2022, 24, 357-358.	0.7	2
5	Wearables, telemedicine, and artificial intelligence in arrhythmias and heart failure: Proceedings of the European Society of Cardiology Cardiovascular Round Table. <i>Europace</i> , 2022, 24, 1372-1383.	0.7	34
6	The Increasing Role of Rhythm Control in Patients With Atrial Fibrillation. <i>Journal of the American College of Cardiology</i> , 2022, 79, 1932-1948.	1.2	63
7	Pandemic-proof recruitment and engagement in a fully decentralized trial in atrial fibrillation patients (DeTAP). <i>Npj Digital Medicine</i> , 2022, 5, .	5.7	11
8	Integration of novel monitoring devices with machine learning technology for scalable cardiovascular management. <i>Nature Reviews Cardiology</i> , 2021, 18, 75-91.	6.1	113
9	2021 ISHNE/HRS/EHRA/APHRS collaborative statement on mHealth in Arrhythmia Management: Digital Medical Tools for Heart Rhythm Professionals. <i>Journal of Arrhythmia</i> , 2021, 37, 271-319.	0.5	21
10	2021 ISHNE/ HRS/ EHRA/ APHRS collaborative statement on mHealth in Arrhythmia Management: Digital Medical Tools for Heart Rhythm Professionals. <i>Annals of Noninvasive Electrocardiology</i> , 2021, 26, e12795.	0.5	29
11	2021 ISHNE/HRS/EHRA/APHRS Expert Collaborative Statement on mHealth in Arrhythmia Management: Digital Medical Tools for Heart Rhythm Professionals: From the International Society for Holter and Noninvasive Electrocardiology/Heart Rhythm Society/European Heart Rhythm Association/Asia-Pacific Heart Rhythm Society. <i>Circulation: Arrhythmia and Electrophysiology</i> . 2021, 14, e009204.	2.1	45
12	2021 ISHNE/HRS/EHRA/APHRS Collaborative Statement on mHealth in Arrhythmia Management: Digital Medical Tools for Heart Rhythm Professionals. <i>Cardiovascular Digital Health Journal</i> , 2021, 2, 4-54.	0.5	10
13	Guideline-Concordant Antiarrhythmic Drug Use in the Get With The Guidelines—Atrial Fibrillation Registry. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2021, 14, e008961.	2.1	11
14	Smart wearable devices in cardiovascular care: where we are and how to move forward. <i>Nature Reviews Cardiology</i> , 2021, 18, 581-599.	6.1	319
15	Why digital health trials can fail: Lessons learned from a randomized trial of health coaching and virtual cardiac rehabilitation. <i>Cardiovascular Digital Health Journal</i> , 2021, 2, 101-108.	0.5	9
16	Patterns of Care for Atrial Fibrillation Before, During, and at Discharge From Hospitalization. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2021, 14, e009003.	2.1	2
17	Factors indicating intention to vaccinate with a COVID-19 vaccine among older U.S. adults. <i>PLoS ONE</i> , 2021, 16, e0251963.	1.1	56
18	Combining Clinical and Polygenic Risk Improves Stroke Prediction Among Individuals With Atrial Fibrillation. <i>Circulation Genomic and Precision Medicine</i> , 2021, 14, e003168.	1.6	24

#	ARTICLE	IF	CITATIONS
19	Efficacy of a centralized, blended electronic, and human intervention to improve direct oral anticoagulant adherence: Smartphones to improve rivaroxaban ADHEREnc in atrial fibrillation (SmartADHERE) a randomized clinical trial. American Heart Journal, 2021, 237, 68-78.	1.2	9
20	Competing Risks, Treatment Switching, and Informative Censoring. JAMA Cardiology, 2021, 6, 871.	3.0	2
21	Performance of first pacemaker to use smart device app for remote monitoring. Heart Rhythm O2, 2021, 2, 463-471.	0.6	17
22	HRS White Paper on Clinical Utilization of Digital Health Technology. Cardiovascular Digital Health Journal, 2021, 2, 196-211.	0.5	9
23	Abstract P120: Feasibility Of An Asynchronous, Semi-Automated Remote Patient Monitoring Blood Pressure Management System. Hypertension, 2021, 78, .	1.3	0
24	Itâ€™s Time to Rethink (and Retrial) Our Framework for Stroke Prevention in Atrial Fibrillation. JAMA Cardiology, 2021, , .	3.0	1
25	Outpatient Prescription Practices in Patients with Atrial Fibrillation (From the NCDR PINNACLE) Tj ETQq1 1 0.784314,rgBT /Oyerlock 10 0,7	0.7	4
26	Arrhythmias Other Than Atrial Fibrillation in Those With an Irregular Pulse Detected With a Smartwatch: Findings From the Apple Heart Study. Circulation: Arrhythmia and Electrophysiology, 2021, 14, e010063.	2.1	23
27	Cardiovascular procedural deferral and outcomes over COVID-19 pandemic phases: A multi-center study. American Heart Journal, 2021, 241, 14-25.	1.2	14
28	Association of kidney function and atrial fibrillation progression to clinical outcomes in patients with cardiac implantable electronic devices. American Heart Journal, 2021, 241, 6-13.	1.2	0
29	Patient characteristics, care patterns, and outcomes of atrial fibrillation associated hospitalizations in patients with chronic kidney disease and end-stage renal disease. American Heart Journal, 2021, 242, 45-60.	1.2	1
30	Research Priorities in Atrial Fibrillation Screening. Circulation, 2021, 143, 372-388.	1.6	42
31	2021 ISHNE / HRS / EHRA / APHRS Collaborative Statement on mHealth in Arrhythmia Management: Digital Medical Tools for Heart Rhythm Professionals. European Heart Journal Digital Health, 2021, 2, 7-48.	0.7	4
32	Procedure characteristics and outcomes of atrial fibrillation ablation procedures using cryoballoon versus radiofrequency ablation: A report from the GWTCâ€™AFIB registry. Journal of Cardiovascular Electrophysiology, 2021, 32, 248-259.	0.8	6
33	Sex Differences in Ablation Strategy, Lesion Sets, and Complications of Catheter Ablation for Atrial Fibrillation: An Analysis From the GWTC-AFIB Registry. Circulation: Arrhythmia and Electrophysiology, 2021, 14, e009790.	2.1	14
34	Anticoagulation Treatment and Outcomes of Venous Thromboembolism by Weight and Body Mass Index: Insights From the Veterans Health Administration. Circulation: Cardiovascular Quality and Outcomes, 2021, 14, e008005.	0.9	10
35	Direct Oral Anticoagulant Adherence of Patients With Atrial Fibrillation Transitioned from Warfarin. Journal of the American Heart Association, 2021, 10, e020904.	1.6	9
36	Appropriateness of Direct Oral Anticoagulant Dosing in Patients With Atrial Fibrillation: Insights From the Veterans Health Administration. Journal of Pharmacy Practice, 2020, 33, 647-653.	0.5	17

#	ARTICLE	IF	CITATIONS
37	Venous Vascular Closure System Versus Manual Compression Following Multiple Access Electrophysiology Procedures. <i>JACC: Clinical Electrophysiology</i> , 2020, 6, 111-124.	1.3	31
38	Diagnosing With a Camera From a Distance—Proceed Cautiously and Responsibly. <i>JAMA Cardiology</i> , 2020, 5, 107.	3.0	9
39	Digital Health and the Care of the Patient With Arrhythmia. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2020, 13, e007953.	2.1	20
40	Social Media Influence Does Not Reflect Scholarly or Clinical Activity in Real Life. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2020, 13, e008847.	2.1	4
41	Incidence and outcomes of patients with atrial fibrillation and major bleeding complications: from the TREAT-AF study. <i>Journal of Interventional Cardiac Electrophysiology</i> , 2020, 62, 133-142.	0.6	2
42	Gerotechnology for Older Adults With Cardiovascular Diseases. <i>Journal of the American College of Cardiology</i> , 2020, 76, 2650-2670.	1.2	66
43	Characteristics and Strength of Evidence of COVID-19 Studies Registered on ClinicalTrials.gov. <i>JAMA Internal Medicine</i> , 2020, 180, 1398.	2.6	54
44	Addressing the New Last-Mile Problem in Health Care With Home-Based Complex Diagnostics. <i>JAMA Cardiology</i> , 2020, 5, 1180.	3.0	0
45	Procedural Patterns and Safety of Atrial Fibrillation Ablation. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2020, 13, e007944.	2.1	42
46	Survey of current perspectives on consumer-available digital health devices for detecting atrial fibrillation. <i>Cardiovascular Digital Health Journal</i> , 2020, 1, 21-29.	0.5	28
47	Sex Differences in Oral Anticoagulation and Outcomes of Stroke and Intracranial Bleeding in Newly Diagnosed Atrial Fibrillation. <i>Journal of the American Heart Association</i> , 2020, 9, e015689.	1.6	36
48	Rationale, considerations, and goals for atrial fibrillation centers of excellence: A Heart Rhythm Society perspective. <i>Heart Rhythm</i> , 2020, 17, 1804-1832.	0.3	38
49	Accuracy of Smartphone Camera Applications for Detecting Atrial Fibrillation. <i>JAMA Network Open</i> , 2020, 3, e202064.	2.8	62
50	Artificial Intelligence and Machine Learning in Arrhythmias and Cardiac Electrophysiology. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2020, 13, e007952.	2.1	96
51	Hydroxychloroquine, Coronavirus Disease 2019, and QT Prolongation. <i>JAMA Cardiology</i> , 2020, 5, 986.	3.0	29
52	Termination of persistent atrial fibrillation by ablating sites that control large atrial areas. <i>Europace</i> , 2020, 22, 897-905.	0.7	15
53	Wearables for arrhythmia care: Challenges and future prospects. <i>Cardiovascular Digital Health Journal</i> , 2020, 1, 56-58.	0.5	1
54	Characterization of cardiac mechanics and incident atrial fibrillation in participants of the Cardiovascular Health Study. <i>JCI Insight</i> , 2020, 5, .	2.3	22

#	ARTICLE	IF	CITATIONS
55	Screening and surveillance of atrial fibrillation with continuous vs. intermittent monitoring: a false choice?. <i>Europace</i> , 2020, 22, 1757-1758.	0.7	1
56	Site Variation and Outcomes for Antithrombotic Therapy in Atrial Fibrillation Patients After Percutaneous Coronary Intervention. <i>Circulation: Cardiovascular Interventions</i> , 2019, 12, e007604.	1.4	10
57	Wavefront Field Mapping Reveals a Physiologic Network Between Drivers Where Ablation Terminates Atrial Fibrillation. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2019, 12, e006835.	2.1	8
58	Large-Scale Assessment of a Smartwatch to Identify Atrial Fibrillation. <i>New England Journal of Medicine</i> , 2019, 381, 1909-1917.	13.9	1,100
59	Technology-Enabled Clinical Trials. <i>Circulation</i> , 2019, 140, 1426-1436.	1.6	59
60	Atrial Fibrillation Burden Signature and Near-Term Prediction of Stroke. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2019, 12, e005595.	0.9	43
61	Transparent sharing of digital health data: A call to action. <i>Heart Rhythm</i> , 2019, 16, e95-e106.	0.3	24
62	Heart Disease and Stroke Statistics—2019 Update: A Report From the American Heart Association. <i>Circulation</i> , 2019, 139, e56-e528.	1.6	6,192
63	Adherence to Guideline-Directed Stroke Prevention Therapy for Atrial Fibrillation Is Achievable. <i>Circulation</i> , 2019, 139, 1497-1506.	1.6	55
64	Urinary tract infection after catheter ablation of atrial fibrillation. <i>PACE - Pacing and Clinical Electrophysiology</i> , 2019, 42, 951-958.	0.5	11
65	Blood Pressure and Incident Atrial Fibrillation in Older Patients Initiating Hemodialysis. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2019, 14, 1029-1038.	2.2	7
66	Comparison of Patient-Reported Care Satisfaction, Quality of Warfarin Therapy, and Outcomes of Atrial Fibrillation: Findings From the ORBIT-AF Registry. <i>Journal of the American Heart Association</i> , 2019, 8, e011205.	1.6	11
67	Comparison of QT Interval Measurement Methods and Correction Formulas in Atrial Fibrillation. <i>American Journal of Cardiology</i> , 2019, 123, 1822-1827.	0.7	24
68	Practice Variation in Anticoagulation Prescription and Outcomes After Device-Detected Atrial Fibrillation. <i>Circulation</i> , 2019, 139, 2502-2512.	1.6	83
69	Characteristics of Digital Health Studies Registered in ClinicalTrials.gov. <i>JAMA Internal Medicine</i> , 2019, 179, 838.	2.6	40
70	Venous access-site closure with vascular closure device vs. manual compression in patients undergoing catheter ablation or left atrial appendage occlusion under uninterrupted anticoagulation: a multicentre experience on efficacy and complications. <i>Europace</i> , 2019, 21, 1048-1054.	0.7	30
71	Management of asymptomatic arrhythmias: a European Heart Rhythm Association (EHRA) consensus document, endorsed by the Heart Failure Association (HFA), Heart Rhythm Society (HRS), Asia Pacific Heart Rhythm Society (APHRS), Cardiac Arrhythmia Society of Southern Africa (CASSA), and Latin America Heart Rhythm Society (LAHRS). <i>Europace</i> , 2019, 21, 844-845.	0.7	68
72	Rationale and design of a large-scale, app-based study to identify cardiac arrhythmias using a smartwatch: The Apple Heart Study. <i>American Heart Journal</i> , 2019, 207, 66-75.	1.2	311

#	ARTICLE	IF	CITATIONS
73	Efficacy of Ablation Lesion Sets in Addition to Pulmonary Vein Isolation for Paroxysmal Atrial Fibrillation: Findings From the SMASH-AF Meta-Analysis Study Cohort. <i>Journal of the American Heart Association</i> , 2019, 8, e009976.	1.6	10
74	Harmonized outcome measures for use in atrial fibrillation patient registries and clinical practice. <i>Heart Rhythm</i> , 2019, 16, e3-e16.	0.3	18
75	Dialysis Modality and Incident Atrial Fibrillation in Older Patients With ESRD. <i>American Journal of Kidney Diseases</i> , 2019, 73, 324-331.	2.1	18
76	A novel pacing maneuver to verify the postpacing interval minus the tachycardia cycle length while adjusting for decremental conduction: Using a dual-chamber entrainment for improved supraventricular tachycardia discrimination. <i>Heart Rhythm</i> , 2019, 16, 717-723.	0.3	5
77	Atrial fibrillation burden, progression, and the risk of death: a case-crossover analysis in patients with cardiac implantable electronic devices. <i>Europace</i> , 2019, 21, 404-413.	0.7	34
78	Cardiologist-level arrhythmia detection and classification in ambulatory electrocardiograms using a deep neural network. <i>Nature Medicine</i> , 2019, 25, 65-69.	15.2	1,633
79	Real-World Comparison of Classes I and III Antiarrhythmic Drugs as an Initial Rhythm Control Strategy in Newly Diagnosed Atrial Fibrillation. <i>JACC: Clinical Electrophysiology</i> , 2019, 5, 231-241.	1.3	8
80	Secular trends in success rate of catheter ablation for atrial fibrillation: The SMASH-AF cohort. <i>American Heart Journal</i> , 2019, 208, 110-119.	1.2	24
81	CHRONIC KIDNEY DISEASE AND ARRHYTHMIAS: CONCLUSIONS FROM A KIDNEY DISEASE: IMPROVING GLOBAL OUTCOMES (KDIGO) CONTROVERSIES CONFERENCE. <i>Nephrology (Saint-Petersburg)</i> , 2019, 23, 18-40.	0.1	5
82	Risk Factors for Symptomatic Atrial Fibrillation-Analysis of an Outpatient Database. <i>Journal of Atrial Fibrillation</i> , 2019, 12, 2141.	0.5	5
83	Risk profiles for acute health events after incident atrial fibrillation in patients with end-stage renal disease on hemodialysis. <i>Nephrology Dialysis Transplantation</i> , 2018, 33, 1590-1597.	0.4	8
84	Digoxin in Atrial Fibrillation?. <i>Journal of the American College of Cardiology</i> , 2018, 71, 1075-1077.	1.2	5
85	Chronic kidney disease and arrhythmias: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. <i>European Heart Journal</i> , 2018, 39, 2314-2325.	1.0	186
86	Geographic and racial representation and reported success rates of studies of catheter ablation for atrial fibrillation: Findings from the SMASH-AF meta-analysis study cohort. <i>Journal of Cardiovascular Electrophysiology</i> , 2018, 29, 747-755.	0.8	11
87	Atrial Fibrillation Burden: Moving Beyond Atrial Fibrillation as a Binary Entity: A Scientific Statement From the American Heart Association. <i>Circulation</i> , 2018, 137, e623-e644.	1.6	279
88	Cost effectiveness of focal impulse and rotor modulation guided ablation added to pulmonary vein isolation for atrial fibrillation. <i>Journal of Cardiovascular Electrophysiology</i> , 2018, 29, 526-536.	0.8	5
89	Independent mapping methods reveal rotational activation near pulmonary veins where atrial fibrillation terminates before pulmonary vein isolation. <i>Journal of Cardiovascular Electrophysiology</i> , 2018, 29, 687-695.	0.8	14
90	Anticoagulant and antiplatelet therapy choices for patients with atrial fibrillation one year after coronary stenting or acute coronary syndrome. <i>Expert Opinion on Drug Safety</i> , 2018, 17, 251-258.	1.0	3

#	ARTICLE	IF	CITATIONS
91	Moving From Big Data to Deep Learningâ€”The Case of Atrial Fibrillation. JAMA Cardiology, 2018, 3, 371.	3.0	10
92	Predictors of oral anticoagulant non-prescription in patients with atrial fibrillation and elevated stroke risk. American Heart Journal, 2018, 200, 24-31.	1.2	41
93	Association of insurance type with receipt of oral anticoagulation in insured patients with atrial fibrillation: A report from the American College of Cardiology NCDR PINNACLE registry. American Heart Journal, 2018, 195, 50-59.	1.2	20
94	2135 Impact of primary care physician gatekeeping on medication prescriptions for atrial fibrillation. Journal of Clinical and Translational Science, 2018, 2, 82-83.	0.3	0
95	Association of Healthcare Plan with atrial fibrillation prescription patterns. Clinical Cardiology, 2018, 41, 1136-1143.	0.7	4
96	Estimated prevalence of undiagnosed atrial fibrillation in the United States. PLoS ONE, 2018, 13, e0195088.	1.1	116
97	Patient and facility variation in costs of catheter ablation for atrial fibrillation. Journal of Cardiovascular Electrophysiology, 2018, 29, 1081-1088.	0.8	9
98	Antithrombotic Therapy for Atrial Fibrillation. Chest, 2018, 154, 1121-1201.	0.4	718
99	Initiating anticoagulation with the intention of cardioverting: does drug choice matter?. European Heart Journal, 2018, 39, 2972-2974.	1.0	2
100	Using Digital Health Technology to Better Generate Evidence and Deliver Evidence-Based Care. Journal of the American College of Cardiology, 2018, 71, 2680-2690.	1.2	192
101	Mobile Health Advances in Physical Activity, Fitness, and Atrial Fibrillation. Journal of the American College of Cardiology, 2018, 71, 2691-2701.	1.2	94
102	Chronic kidney disease and arrhythmias: highlights from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Kidney International, 2018, 94, 231-234.	2.6	26
103	Atrial Fibrillation Diagnosis Timing, Ambulatory ECG Monitoring Utilization, and Risk of Recurrent Stroke. Circulation: Cardiovascular Quality and Outcomes, 2017, 10, .	0.9	42
104	Long-term electrocardiographic safety monitoring in clinical drug development: A report from the Cardiac Safety Research Consortium. American Heart Journal, 2017, 187, 156-169.	1.2	11
105	Healthcare Utilization and Expenditures Associated With Appropriate and Inappropriate Implantable Defibrillator Shocks. Circulation: Cardiovascular Quality and Outcomes, 2017, 10, .	0.9	22
106	Warfarin utilisation and anticoagulation control in patients with atrial fibrillation and chronic kidney disease. Heart, 2017, 103, 818-826.	1.2	78
107	Contemporary Trends in Oral Anticoagulant Prescription in Atrial Fibrillation Patients at Low to Moderate Risk of Stroke After Guideline-Recommended Change in Use of the CHADS ₂ to the CHA ₂ DS ₂ -VASc Score for Thromboembolic Risk Assessment. Circulation: Cardiovascular Quality and Outcomes. 2017, 10, .	0.9	60
108	Screening for Atrial Fibrillation. Circulation, 2017, 135, 1851-1867.	1.6	453

#	ARTICLE	IF	CITATIONS
109	2017 ISHNE-HRS expert consensus statement on ambulatory ECG and external cardiac monitoring/telemetry. , 2017, 22, e12447.		52
110	Factors associated with rhythm control treatment decisions in patients with atrial fibrillation—Insights from the NCDR PINNACLE registry. American Heart Journal, 2017, 187, 88-97.	1.2	10
111	Early non-persistence with dabigatran and rivaroxaban in patients with atrial fibrillation. Heart, 2017, 103, 1331-1338.	1.2	69
112	Telemedicine for Management of Implantable Defibrillators. Circulation: Arrhythmia and Electrophysiology, 2017, 10, .	2.1	3
113	Reply. Journal of the American College of Cardiology, 2017, 70, 2730-2731.	1.2	0
114	Treating Specialty and Outcomes in Newly Diagnosed Atrial Fibrillation. Journal of the American College of Cardiology, 2017, 70, 78-86.	1.2	54
115	Risk and Consequences of Atrial Fibrillation. JAMA Cardiology, 2017, 2, 871.	3.0	1
116	Impact of Baseline Stroke Risk and Bleeding Risk on Warfarin International Normalized Ratio Control in Atrial Fibrillation (from the TREAT-AF Study). American Journal of Cardiology, 2017, 119, 268-274.	0.7	12
117	Safety and Clinical Outcomes of Catheter Ablation of Atrial Fibrillation in Patients With Chronic Kidney Disease. Journal of Cardiovascular Electrophysiology, 2017, 28, 39-48.	0.8	24
118	Survival After Secondary Prevention Implantable Cardioverter-Defibrillator Placement. JACC: Clinical Electrophysiology, 2017, 3, 20-28.	1.3	14
119	Screening for atrial fibrillation: a European Heart Rhythm Association (EHRA) consensus document endorsed by the Heart Rhythm Society (HRS), Asia Pacific Heart Rhythm Society (APHRS), and Sociedad Latinoamericana de Estimulaci3n Card3aca y Electrofisiolog3a (SOLAECE). Europace, 2017, 19, 1589-1623.	0.7	208
120	Pharmacokinetics of Tecarfarin and Warfarin in Patients with Severe Chronic Kidney Disease. Thrombosis and Haemostasis, 2017, 117, 2026-2033.	1.8	14
121	Adherence and outcomes to direct oral anticoagulants among patients with atrial fibrillation: findings from the veterans health administration. BMC Cardiovascular Disorders, 2017, 17, 236.	0.7	125
122	Stroke Risk Stratification in Atrial Fibrillation: Bridging the Evidence Gaps. Journal of Cardiovascular Electrophysiology, 2016, 27, 271-273.	0.8	4
123	Sleep disordered breathing and cardiovascular risk in older patients initiating dialysis in the United States: a retrospective observational study using medicare data. BMC Nephrology, 2016, 17, 16.	0.8	26
124	Electrocardiographic Early Repolarization. Circulation, 2016, 133, 1520-1529.	1.6	97
125	Gender Differences in Clinical Outcomes After Catheter Ablation of Atrial Fibrillation. JACC: Clinical Electrophysiology, 2016, 2, 703-710.	1.3	70
126	Guideline Directed Medication Use in Patients With Heart Failure With Reduced Ejection Fraction in India: American College of Cardiology's PINNACLE India Quality Improvement Program. Clinical Cardiology, 2016, 39, 145-149.	0.7	22

#	ARTICLE	IF	CITATIONS
127	The Outlook of Digital Health for Cardiovascular Medicine. JAMA Cardiology, 2016, 1, 743.	3.0	42
128	International Collaborative Partnership for the Study of Atrial Fibrillation (INTERAF): Rationale, Design, and Initial Descriptives. Journal of the American Heart Association, 2016, 5, .	1.6	18
129	Defining a Mobile Health Roadmap for Cardiovascular Health and Disease. Journal of the American Heart Association, 2016, 5, .	1.6	38
130	Aspirin Instead of Oral Anticoagulant Prescription in Atrial Fibrillation Patients at Risk for Stroke. Journal of the American College of Cardiology, 2016, 67, 2913-2923.	1.2	119
131	Cost-Effectiveness of Percutaneous Closure of the Left Atrial Appendage in Atrial Fibrillation Based on Results From PROTECT AF Versus PREVAIL. Circulation: Arrhythmia and Electrophysiology, 2016, 9, .	2.1	17
132	Reduced Mortality Associated With Quadripolar Compared to Bipolar Left Ventricular Leads in Cardiac Resynchronization Therapy. JACC: Clinical Electrophysiology, 2016, 2, 426-433.	1.3	41
133	Comparative Effectiveness of Cardiac Resynchronization Therapy Among Patients With Heart Failure and Atrial Fibrillation. Circulation: Heart Failure, 2016, 9, .	1.6	13
134	Transforming the care of atrial fibrillation with mobile health. Journal of Interventional Cardiac Electrophysiology, 2016, 47, 45-50.	0.6	38
135	Racial Differences in Quality of Anticoagulation Therapy for Atrial Fibrillation (from the TREAT-AF) Tj ETQq1 1 0.784314 rgBT /Overlock 0.7 29		
136	Oral Anticoagulant Therapy Prescription in Patients With Atrial Fibrillation Across the Spectrum of Stroke Risk. JAMA Cardiology, 2016, 1, 55.	3.0	249
137	Cost-Effectiveness of Implantable Pulmonary Artery Pressure Monitoring in Chronic Heart Failure. JACC: Heart Failure, 2016, 4, 368-375.	1.9	74
138	The precise timing of tachycardia entrainment is determined by the postpacing interval, the tachycardia cycle length, and the pacing rate: Theoretical insights and practical applications. Heart Rhythm, 2016, 13, 695-703.	0.3	24
139	Utilization and likelihood of radiologic diagnostic imaging in patients with implantable cardiac defibrillators. Journal of Magnetic Resonance Imaging, 2016, 43, 115-127.	1.9	49
140	Cost-Effectiveness of Cardiac Radiosurgery for Atrial Fibrillation: Implications for Reducing Health Care Morbidity, Utilization, and Costs. Cureus, 2016, 8, e720.	0.2	8
141	Feasibility of Extended Ambulatory Electrocardiogram Monitoring to Identify Silent Atrial Fibrillation in High-risk Patients: The Screening Study for Undiagnosed Atrial Fibrillation (STUDY AF). Clinical Cardiology, 2015, 38, 285-292.	0.7	86
142	Cardiovascular Disease Performance Measures in the Outpatient Setting in India: Insights From the American College of Cardiology's PINNACLE India Quality Improvement Program (PIQIP). Journal of the American Heart Association, 2015, 4, .	1.6	13
143	Does Age Influence Cardiac Resynchronization Therapy Use and Outcome?. JACC: Heart Failure, 2015, 3, 497-504.	1.9	17
144	Safety of Ventricular Tachycardia Ablation in Clinical Practice. Circulation: Arrhythmia and Electrophysiology, 2015, 8, 362-370.	2.1	53

#	ARTICLE	IF	CITATIONS
145	Correlates and outcomes of warfarin initiation in kidney transplant recipients newly diagnosed with atrial fibrillation. <i>Nephrology Dialysis Transplantation</i> , 2015, 30, 321-329.	0.4	17
146	Reply. <i>Journal of the American College of Cardiology</i> , 2015, 65, 221.	1.2	4
147	Innovative designs of point-of-care comparative effectiveness trials. <i>Contemporary Clinical Trials</i> , 2015, 45, 61-68.	0.8	16
148	Defibrillator implantations for primary prevention in the United States: Inappropriate care or inadequate documentation: Insights from the National Cardiovascular Data ICD Registry. <i>Heart Rhythm</i> , 2015, 12, 2086-2093.	0.3	7
149	Chronic kidney disease in patients with cardiac rhythm disturbances or implantable electrical devices: clinical significance and implications for decision making—a position paper of the European Heart Rhythm Association endorsed by the Heart Rhythm Society and the Asia Pacific Heart Rhythm Society. <i>Europace</i> , 2015, 17, 1169-1196.	0.7	138
150	Economic Burden of Undiagnosed Nonvalvular Atrial Fibrillation in the United States. <i>American Journal of Cardiology</i> , 2015, 116, 733-739.	0.7	73
151	Atrial Fibrillation Burden and Short-Term Risk of Stroke. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2015, 8, 1040-1047.	2.1	168
152	Site-Level Variation in and Practices Associated With Dabigatran Adherence. <i>JAMA - Journal of the American Medical Association</i> , 2015, 313, 1443.	3.8	124
153	Early detection of occult atrial fibrillation and stroke prevention. <i>Heart</i> , 2015, 101, 1097-1102.	1.2	37
154	Outcomes After Warfarin Initiation in a Cohort of Hemodialysis Patients With Newly Diagnosed Atrial Fibrillation. <i>American Journal of Kidney Diseases</i> , 2015, 66, 677-688.	2.1	119
155	A validated risk model for 1-year mortality after primary prevention implantable cardioverter defibrillator placement. <i>American Heart Journal</i> , 2015, 170, 281-289.e2.	1.2	18
156	Individual and Combined Risk Factors for Incident Atrial Fibrillation and Incident Stroke: An Analysis of 3 Million At-Risk US Patients. <i>Journal of the American Heart Association</i> , 2015, 4, .	1.6	30
157	Amiodarone and risk of death in contemporary patients with atrial fibrillation: Findings from The Retrospective Evaluation and Assessment of Therapies in AF study. <i>American Heart Journal</i> , 2015, 170, 1033-1041.e1.	1.2	14
158	Effectiveness of a community screening program for metabolic syndrome and cardiovascular risk factor identification in young South Asians adults. <i>Diabetes and Metabolic Syndrome: Clinical Research and Reviews</i> , 2015, 9, 38-41.	1.8	5
159	Regarding “Feasibility and Safety of Same-Day Discharge after Implantable Cardioverter Defibrillator Placement for Primary Prevention” <i>PACE - Pacing and Clinical Electrophysiology</i> , 2014, 37, 131-131.	0.5	0
160	Phenytoin Toxicity Unlikely to Result in Arrhythmias”Reply. <i>JAMA Internal Medicine</i> , 2014, 174, 167.	2.6	0
161	Clinical Reminders to Providers of Patients With Reduced Left Ventricular Ejection Fraction Increase Defibrillator Referral. <i>Circulation: Heart Failure</i> , 2014, 7, 140-145.	1.6	13
162	Association Between Success Rate and Citation Count of Studies of Radiofrequency Catheter Ablation for Atrial Fibrillation. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2014, 7, 687-692.	0.9	13

#	ARTICLE	IF	CITATIONS
163	Get With The Guidelines AFIB. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2014, 7, 770-777.	0.9	45
164	Adherence and Persistence in the Use of Warfarin After Hospital Discharge Among Patients With Heart Failure and Atrial Fibrillation. <i>Journal of Cardiac Failure</i> , 2014, 20, 23-30.	0.7	20
165	Warfarin Treatment in Patients With Atrial Fibrillation and Advanced Chronic Kidney Disease. <i>JAMA - Journal of the American Medical Association</i> , 2014, 311, 913.	3.8	17
166	Association of CHADS2, CHA2DS2-VASc, and R2CHADS2 Scores With Left Atrial Dysfunction in Patients With Coronary Heart Disease (from the Heart and Soul Study). <i>American Journal of Cardiology</i> , 2014, 113, 1166-1172.	0.7	16
167	Adherence to dabigatran therapy and longitudinal patient outcomes: Insights from the Veterans Health Administration. <i>American Heart Journal</i> , 2014, 167, 810-817.	1.2	207
168	Increased Mortality Associated With Digoxin in Contemporary Patients With Atrial Fibrillation. <i>Journal of the American College of Cardiology</i> , 2014, 64, 660-668.	1.2	189
169	Relation of Left Atrial Dysfunction to Ischemic Stroke in Patients With Coronary Heart Disease (from the TIMESTOP Study). <i>Journal of the American College of Cardiology</i> , 2014, 64, 1082-1089.	0.7	32
170	Diagnostic Yield of Extended Cardiac Patch Monitoring in Patients with Stroke or TIA. <i>Frontiers in Neurology</i> , 2014, 5, 266.	1.1	47
171	Evaluating the Cost-effectiveness of Catheter Ablation of Atrial Fibrillation. <i>Arrhythmia and Electrophysiology Review</i> , 2014, 3, 177.	1.3	17
172	US Health Care Policy and Reform: implications for cardiac electrophysiology. <i>Journal of Interventional Cardiac Electrophysiology</i> , 2013, 36, 129-136.	0.6	3
173	Diagnostic Utility of a Novel Leadless Arrhythmia Monitoring Device. <i>American Journal of Cardiology</i> , 2013, 112, 520-524.	0.7	198
174	Differences and trends in stroke prevention anticoagulation in primary care vs cardiology specialty management of new atrial fibrillation: The Retrospective Evaluation and Assessment of Therapies in AF (TREAT-AF) study. <i>American Heart Journal</i> , 2013, 165, 93-101.e1.	1.2	72
175	Burden, timing, and relationship of cardiovascular hospitalization to mortality among Medicare beneficiaries with newly diagnosed atrial fibrillation. <i>American Heart Journal</i> , 2013, 166, 573-580.	1.2	19
176	Comparative effectiveness of antiarrhythmic drugs on cardiovascular hospitalization and mortality in atrial fibrillation. <i>Journal of Comparative Effectiveness Research</i> , 2013, 2, 301-312.	0.6	2
177	Bizarre and Wide QRS After Liver Transplant—Quiz Case. <i>JAMA Internal Medicine</i> , 2013, 173, 953.	2.6	3
178	Abstract 315: Feasibility of outpatient ambulatory ECG monitoring to screen for silent atrial fibrillation: Pilot Findings from Screening Trial for Undiagnosed Atrial Fibrillation (STUDY-AF). <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2013, 6, .	0.9	0
179	Latency of ECG Displays of Hospital Telemetry Systems. <i>Circulation</i> , 2012, 126, 1665-1669.	1.6	7
180	Oral Antithrombotic Agents for the Prevention of Stroke in Nonvalvular Atrial Fibrillation. <i>Stroke</i> , 2012, 43, 3442-3453.	1.0	248

#	ARTICLE	IF	CITATIONS
181	Cost-effectiveness of pharmacologic and invasive therapies for stroke prophylaxis in atrial fibrillation. <i>Journal of Cardiovascular Medicine</i> , 2012, 13, 86-96.	0.6	12
182	Ability of microvolt T-wave alternans to modify risk assessment of ventricular tachyarrhythmic events: A meta-analysis. <i>American Heart Journal</i> , 2012, 163, 354-364.	1.2	35
183	Reply: Ability of microvolt T-wave alternans to modify risk assessment of ventricular tachyarrhythmic events: A meta-analysis. <i>American Heart Journal</i> , 2012, 164, e9-e10.	1.2	0
184	Left Atrial Function Predicts Heart Failure Hospitalization in Subjects With Preserved Ejection Fraction and Coronary Heart Disease. <i>Journal of the American College of Cardiology</i> , 2012, 59, 673-680.	1.2	125
185	Incidence and clinical predictors of low defibrillation safety margin at time of implantable defibrillator implantation. <i>Journal of Interventional Cardiac Electrophysiology</i> , 2012, 34, 93-100.	0.6	6
186	Abstract P199: Mean Lipoprotein Levels and Composition in South Asian-Americans Compared to the US Population. <i>Circulation</i> , 2012, 125, .	1.6	0
187	The CHADS2 score predicts ischemic stroke in the absence of atrial fibrillation among subjects with coronary heart disease: Data from the Heart and Soul Study. <i>American Heart Journal</i> , 2011, 162, 555-561.	1.2	98
188	Dabigatran Compared With Warfarin for Stroke Prevention in Atrial Fibrillation. <i>Annals of Internal Medicine</i> , 2011, 154, 570.	2.0	17
189	Cost-Effectiveness of Dabigatran Compared With Warfarin for Stroke Prevention in Atrial Fibrillation. <i>Annals of Internal Medicine</i> , 2011, 154, 1.	2.0	363
190	JICE goes "social". <i>Journal of Interventional Cardiac Electrophysiology</i> , 2011, 32, 79-80.	0.6	4
191	Quality of Stroke Prevention Care in Atrial Fibrillation. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2011, 4, 5-8.	0.9	5
192	Prevalence of Metabolic Syndrome in South Asians Residing in the United States. <i>Metabolic Syndrome and Related Disorders</i> , 2010, 8, 417-423.	0.5	25
193	Predicting Heart Failure Hospitalization and Mortality by Quantitative Echocardiography: Is Body Surface Area the Indexing Method of Choice? The Heart and Soul Study. <i>Journal of the American Society of Echocardiography</i> , 2010, 23, 406-413.	1.2	26
194	Developing the Safety of Atrial Fibrillation Ablation Registry Initiative (SAFARI) as a collaborative pan-stakeholder critical path registry model: A Cardiac Safety Research Consortium "Incubator" Think Tank. <i>American Heart Journal</i> , 2010, 160, 619-626.e1.	1.2	16
195	Sudden cardiac death and implantable cardioverter-defibrillators. <i>American Family Physician</i> , 2010, 82, 1357-66.	0.1	9
196	Increase in end-systolic volume after exercise independently predicts mortality in patients with coronary heart disease: data from the Heart and Soul Study. <i>European Heart Journal</i> , 2009, 30, 2478-2484.	1.0	24
197	Polymorphic ventricular tachycardia?. <i>Journal of Hospital Medicine</i> , 2009, 4, 140-141.	0.7	1
198	Rates and severity of perforation from implantable cardioverter-defibrillator leads: A 4-year study. <i>Journal of Interventional Cardiac Electrophysiology</i> , 2009, 24, 47-52.	0.6	21

#	ARTICLE	IF	CITATIONS
199	â€œLow ejection fraction prophylaxisâ€•with implantable defibrillators in the elderly: Call for a randomized trial?. Heart Rhythm, 2009, 6, 1144-1145.	0.3	1
200	Wolff-Parkinson-White syndrome: where is the pathway?. Indian Pacing and Electrophysiology Journal, 2009, 9, 130-3.	0.3	2
201	Knowledge and attitudes of primary care physicians in the management of patients at risk for cardiovascular events. BMC Family Practice, 2008, 9, 42.	2.9	75
202	The irritable heart. Journal of Hospital Medicine, 2008, 3, 423-429.	0.7	1
203	Impact of Remote Magnetic Catheter Navigation on Ablation Fluoroscopy and Procedure Time. PACE - Pacing and Clinical Electrophysiology, 2008, 31, 1399-1404.	0.5	60
204	Impact of advanced age on survival in patients with implantable cardioverter defibrillators. Europace, 2008, 10, 1296-1301.	0.7	46
205	Sudden Cardiac Death: Epidemiology, Mechanisms, and Therapy. Current Problems in Cardiology, 2007, 32, 501-546.	1.1	71
206	Lessons learned in the Apple Heart Study and implications for the data management of future digital clinical trials. Journal of Biopharmaceutical Statistics, 0, , 1-15.	0.4	4